Matinas BioPharma Holdings Inc (MTNB)
0.6404
-0.07
(-9.80%)
USD |
NYAM |
Nov 14, 16:00
0.6306
-0.01
(-1.53%)
After-Hours: 20:00
Matinas BioPharma Holdings Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2023 | 1.096M |
| December 31, 2022 | 1.063M |
| September 30, 2022 | 1.063M |
| June 30, 2022 | 1.063M |
| March 31, 2022 | |
| December 31, 2021 | -0.0003M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 0.0333M |
| December 31, 2020 | 0.0625M |
| September 30, 2020 | 0.0958M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 0.0898M |
| March 31, 2019 |
| Date | Value |
|---|---|
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 0.0898M |
| March 31, 2018 | 0.0299M |
| December 31, 2017 | 0.0449M |
| September 30, 2017 | 0.0449M |
| June 30, 2017 | 0.0449M |
| March 31, 2017 | 0.015M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | 0.0599M |
| June 30, 2015 | 0.077M |
| March 31, 2015 | 0.0576M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.0003M
Minimum
Dec 2021
1.096M
Maximum
Mar 2023
0.5595M
Average
0.5794M
Median
Revenue (Quarterly) Benchmarks
| Equillium Inc | 13.85M |
| Tenon Medical Inc | 0.901M |
| Alphatec Holdings Inc | 150.72M |
| Merck & Co Inc | 16.66B |
| Madrigal Pharmaceuticals Inc | 62.18M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.719M |
| Total Expenses (Quarterly) | 5.839M |
| EPS Diluted (Quarterly) | -1.00 |
| Enterprise Value | -10.75M |
| Earnings Yield | -858.8% |
| Normalized Earnings Yield | -922.09 |